

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, January 29, 2016 – Astellas Pharma Inc. (Tokyo : 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Reasons for the acquisition of own shares
To improve capital efficiency and shareholder return.
2. Contents of acquisition
 - (1) Class of shares to be acquired: Common stock of the Company
 - (2) Total number of shares to be acquired: Up to 17 million shares
(The percentage compared to the total number of shares outstanding: 0.79 %)
 - (3) Aggregate amount of acquisition cost: Up to 30 billion yen
 - (4) Period of acquisition: From February 1, 2016 to March 11, 2016

(Reference)

The status of treasury shares as of December 31, 2015:

Total number of shares outstanding:	2,141,845,843 shares
Number of treasury shares:	79,977,332 shares

#####

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 http://www.astellas.com/en